Concord Biotech Gains Momentum on Key USFDA Approval

$CONCORDBIO continued its strong upward trajectory, marking its third consecutive winning session. In morning trade, the stock surged nearly 9%, significantly outperforming the broader market, which remained under pressure. Investor sentiment was boosted after the company received USFDA approval for its ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. The drug is an important immunosuppressant used to prevent organ rejection in kidney, heart, and liver transplant recipients. The approval strengthens Concord Biotech’s presence in regulated markets and is viewed as a positive development for its long-term growth prospects. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.